5-氨基-3-环己基异噁唑 | 500766-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氨基-3-环己基异噁唑
• 中文别名: 3-环己基并异噻唑-5-胺
• 英文名称: 3-cyclohexylisoxazol-5-amine
• 英文别名: 3-cyclohexyl-5-aminoisoxazole；3-Cyclohexyl-1,2-oxazol-5-amine
• CAS: 500766-46-1
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: VQZCMFOELVYEHV-UHFFFAOYSA-N

物化性质

• 沸点：
  328.4±30.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-氨基-3-环己基异噁唑 在 iron(II) chloride tetrahydrate 作用下， 以 乙腈 为溶剂， 以81%的产率得到3-cyclohexyl-2H-azirine-2-carboxamide
  参考文献：
  名称：

  2H-Azirines作为生物共轭技术中半胱氨酸残基的潜在双功能化学连接物。

  摘要：

  2H-Azirine-2-caboxamides被设计为在非常温和的反应条件下充当新型的双功能硫醇连接基。2H-叠氮基的CN双键的裂解通过硫醇加成和开环过程原位提供氨基酰胺官能团。在室温下不存在任何催化剂的情况下，它可与各种硫醇和2H-叠氮基一起使用。还证明了含半胱氨酸的肽可以在完全水溶液中有效地起作用。

  DOI：

  10.1021/acs.orglett.0c00415
• 作为产物：
  描述：

  环己甲酸乙酯 在 盐酸羟胺 、 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 、 mineral oil 为溶剂， 生成 5-氨基-3-环己基异噁唑
  参考文献：
  名称：

  Identification of diphenylalkylisoxazol-5-amine scaffold as novel activator of cardiac myosin

  摘要：

  To identify novel potent cardiac myosin activator, a series of diphenylalkylisoxazol-5-amine compounds 4-7 have been synthesized and evaluated for cardiac myosin ATPase activation. Among the 37 compounds, 4a (CMA at 10 µM = 81.6%), 4w (CMA at 10 µM = 71.2%) and 6b (CMA at 10 µM = 67.4%) showed potent cardiac myosin activation at a single concentration of 10 µM. These results suggested that the introduction of the amino-isoxazole ring as a bioisostere for urea group is acceptable for the cardiac myosin activation. Additional structure-activity relationship (SAR) studies were conducted. Para substitution (-Cl, -OCH₃, -SO₂N(CH₃)₂) to the phenyl rings or replacement of a phenyl ring with a heterocycle (pyridine, piperidine and tetrahydropyran) appeared to attenuate cardiac myosin activation at 10 µM. Additional hydrogen bonding acceptor next to the amino group of the isoxazoles did not enhance the activity. The potent isoxazole compounds showed selectivity for cardiac myosin activation over skeletal and smooth muscle myosin, and therefore these potent and selective isoxazole compounds could be considered as a new series of cardiac myosin ATPase activators for the treatment of systolic heart failure.

  DOI：

  10.1016/j.bmc.2020.115742

文献信息

• Amino-substituted pyrimidinyl derivatives and methods of use
  申请人：——

  公开号：US20030125346A1

  公开（公告）日：2003-07-03

  The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.

  这项发明涵盖了化合物、类似物、前药和其药学上可接受的衍生物，以及用于预防和治疗癌症的药物组合物、用途和方法。
• [EN] PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVATIFS DE PYRIDINESULFONAMIDE POUVANT ÊTRE UTILISÉS COMME MODULATEURS TRAP1 ET LEURS UTILISATIONS
  申请人：AMATHUS THERAPEUTICS INC

  公开号：WO2021188907A1

  公开（公告）日：2021-09-23

  The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as a-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

  本公开提供了化合物的化学式（I）和药学上可接受的盐、溶剂化合物、水合物、多晶型、共晶体、互变异构体、立体异构体、同位素标记化合物以及其前药。所提供的化合物可能是肿瘤坏死因子（"TNF"）受体相关蛋白1（"TRAP1"）调节剂（例如，TRAP1激活剂）。所提供的化合物还可能恢复PTEN诱导的激酶1（"PINK1"）功能丧失情况下的活性。所提供的化合物还可能改善线粒体的健康、功能、质量、数量和/或活性，和/或减少活性氧自由基的产生。所提供的化合物还可能对聚集或错误折叠的蛋白质（如α-突触核蛋白）进行重折叠或溶解。本公开还提供了包括所提供化合物的药物组合物；包括所提供化合物或药物组合物的试剂盒；以及使用所提供的化合物和药物组合物的方法（例如，用于治疗需要的受试者的疾病）。
• Hoveyda–Grubbs II Catalyst: A Useful Catalyst for One-Pot Visible-Light-Promoted Ring Contraction and Olefin Metathesis Reactions
  作者：Yun Ge、Wangbin Sun、Bingbing Pei、Jia Ding、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1021/acs.orglett.8b00971

  日期：2018.5.4

  A one-pot reaction to synthesize functionalized 2H-azirines through visible-light-mediated ring contraction and olefin metathesis of isoxazoles is described. Hoveyda–Grubbs II catalyst was found to function as a photocatalyst for these transformations, allowing these processes to be carried out in a one-pot manner. This study offers a new entry for the application of Grubbs catalysts as efficient photocatalysts

  描述了通过可见光介导的环收缩和异恶唑的烯烃复分解反应合成官能化2 H-叠氮基的一锅反应。发现Hoveyda–Grubbs II催化剂可作为这些转化的光催化剂，使这些过程可以一锅法进行。这项研究为将Grubbs催化剂用作有效的光催化剂提供了一个新的切入点，并且为一锅法进行其他光反应和烯烃复分解提供了可能性。
• Reactions of 5-Aminoisoxazoles with α-Diazocarbonyl Compounds: Wolff Rearrangement vs N–H Insertion
  作者：Yun Ge、Wangbin Sun、Yang Chen、Yulin Huang、Zhuang Liu、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1021/acs.joc.8b02986

  日期：2019.3.1

  chemoselective reaction between 5-aminoisoxazoles and α-diazocarbonyl compounds has been described. Both Wolff rearrangement and N–H insertion products can be obtained selectively by the judicious choice of reaction conditions. In the case of the Wolff rearrangement reactions, the N-isoxazole amides are accessed as the sole products under thermal conditions. On the other hand, α-amino acid derivatives

  已经描述了5-氨基异恶唑和α-重氮羰基化合物之间的高度化学选择性反应。通过明智地选择反应条件，可以有选择地获得Wolff重排和N–H插入产物。在沃尔夫夫重排反应的情况下，在热条件下，N-异恶唑酰胺是唯一的产物。另一方面，在催化性Rh 2（Oct）4的存在下，可以通过NH插入反应获得N-异恶唑的α-氨基酸衍生物。两种反应均在温和的反应条件下进行，并具有广泛的底物范围。
• [EN] ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES ISOXAZOLIQUES ET ISOTHIAZOLIQUES DESTINES AU TRAITEMENT DE TROUBLES NEURODEGENERATIFS
  申请人：PFIZER PROD INC

  公开号：WO2004099200A1

  公开（公告）日：2004-11-18

  The present invention relates to compounds of the Formula I wherein R3, R5, R6, R7, X, Y and Z are as defined. Compounds of the Formula I have activity 5 inhibiting production of Aβ-peptide. This invention also relates to pharmaceutical compositions and methods of treating diseases, for example, neurodegenerative diseases, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.

  本发明涉及公式I的化合物，其中R3、R5、R6、R7、X、Y和Z如定义所述。公式I的化合物具有抑制Aβ肽产生的活性。本发明还涉及包括公式I的化合物在内的药物组合物和治疗疾病的方法，例如神经退行性疾病，例如阿尔茨海默病，在哺乳动物中。